InvestSMART

EVE Health Group Limited (ASX:EVE)

ALERT: Price-sensitive ASX Announcement for EVE
Current share price for EVE : $0.015 0.001 (7.14%)+
Announcement
Release
31 Aug 2026 5:18PM
Price at Release
$0.014
Full Release
download
Summary
EVE Health Group Limited’s Appendix 4E Results for Announcement to the Market for the financial year ended 30 June 2026 reports revenue from ordinary activities of $1,153,101, down 33.53% from the prior financial year ended 30 June 2025, while loss after tax from continuing operations attributable to members increased 30.13% to $1,890,753 and net loss attributable to members increased 19.67% to $1,890,753; net tangible assets per ordinary security were $0.0031 compared with $0.0023 in 2025, no dividends were paid, declared or determined during the year, there were no associates or joint venture entities and no entities over which control was gained or lost, and the announcement states that the underlying consolidated financial statements were audited with further commentary contained in the 2026 Annual Report; it also describes EVE as an Australian-based health company developing and commercialising evidence-based wellness and pharmaceutical products through subsidiaries including Meluka Australia and Nextract.
Key Points
  • Appendix 4E covers EVE Health Group and its controlled entities for the financial year ended 30 June 2026 compared with the year ended 30 June 2025.
  • Revenue from ordinary activities fell 33.53% to $1,153,101.
  • Loss after tax from continuing operations attributable to members increased 30.13% to $1,890,753.
  • Net loss for the period attributable to members increased 19.67% to $1,890,753.
  • Net tangible assets per ordinary security were $0.0031, up from $0.0023 in 2025.
  • No dividends were paid, declared or determined during the reporting period.
  • There were no associates or joint venture entities.
  • There were no entities over which control was gained or lost during the period.
  • The consolidated financial statements underlying the Appendix 4E were audited and the auditor’s report is included in the 2026 Annual Report.
  • EVE Health Group is described as an Australian-based health company developing and commercialising evidence-based wellness and pharmaceutical products through Meluka Australia and Nextract.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.